about
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinicCeramide synthesis regulates T cell activity and GVHD development.HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host DiseaseMicroRNA-31 negatively regulates peripherally derived regulatory T-cell generation by repressing retinoic acid-inducible protein 3.Regulatory T-Cell Therapy for Graft-versus-host Disease.STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity.Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation.Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantationCD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.T-Cell Metabolism in Hematopoietic Cell Transplantation.PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Anti-Tumor T Cell ResponseThe IL-12 Cytokine and Receptor Family in Graft-vs.-Host DiseaseStabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host DiseaseThioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host diseaseVitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapseIL-27 Receptor Signaling on T cells Augments GVHD Severity through Enhancing Th1 ResponsesThioredoxin-1 improves the immunometabolic phenotype of antitumor T cells
P50
Q28075992-D8BBCBAA-93F0-43F2-927B-C3A49269A44AQ33703218-F2E59D57-6192-466C-B6E2-0A4B812FC230Q35815893-CD2C9057-DEE1-4FB8-8D38-508C360A4E94Q35877614-83F42BCF-6E5B-4D63-8727-5F26DB2E984AQ37309438-A77801EA-1359-42F3-AF49-1E1AFC8777A5Q37496786-84FFB857-4C74-46BF-8AE9-58BC9F4284F6Q38202009-735E1846-B09D-43FD-9A05-53375FC6DB0EQ38839120-A2B1A426-636D-4C58-96BD-FBD7A2B2B425Q39617623-CB6D6D4B-5C55-4695-A89B-F6E56F2A014DQ50054341-9B08A43D-0D03-4824-9C09-554F88028872Q52686035-6A985DC1-3B84-47FD-94F2-A37B4C6E51DAQ54978680-D99FC2AF-43C6-464C-98B1-CCBB54D6D7DCQ57456561-1F44F0F6-E883-4EC0-8917-C056533E7E63Q64257524-1AA66B66-1BDC-4275-9B92-EF78E8EE3E34Q91637969-F12106A1-2AA8-419B-AB60-523EFC1FCC5BQ91691311-46304A43-F2FA-4AFC-98AC-C38AB19C3C8DQ92124664-950429FC-6D8A-4CF9-BE50-E73515E1CC4DQ92587865-E6002AE2-4882-4BD8-8F20-9C2E389497E4Q93010613-3FB40376-8141-472C-AE95-52C3A0A2A6FF
P50
description
researcher (ORCID 0000-0002-1751-2884)
@en
name
Xue-Zhong Yu
@en
type
label
Xue-Zhong Yu
@en
prefLabel
Xue-Zhong Yu
@en
P31
P496
0000-0002-1751-2884